WB
H M R Mk
Endogenous
104, 109
Rabbit
#Q13107
7375
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Species predicted to react based on 100% sequence homology
The antigen sequence used to produce this antibody shares
100% sequence homology with the species listed here, but
reactivity has not been tested or confirmed to work by CST.
Use of this product with these species is not covered under
our
Product Performance Guarantee.
Dog
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His666 of human USP4 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Ubiquitinating enzymes (UBEs) catalyze protein ubiquitination, a reversible process countered by deubiquitinating enzyme (DUB) action (1,2). Five DUB subfamilies are recognized, including the USP, UCH, OTU, MJD, and JAMM enzymes. USP4 was originally identified during a survey of murine genes near the Mpv20 retroviral insertion site and intially referred to as Ubiquitous Nuclear Protein (UNP). Analysis of the mouse cDNA originally identified Usp4/Unp as a proto-oncogene related to the human tre-2/tre-17/USP6 proto-oncogene (3,4). Usp4/Unp was subsequently observed to contain the conserved Cys and His boxes of the UBP family (5,6) as well as DUB activity (7,8). In a study of primary lung tumor tissue, it was observed that the human homolog of Usp4, USP4/UNPH, had elevated gene expression levels in small cell tumors and adenocarcinomas of the lung, suggesting a causative role for USP4 in neoplasia (6). Another recent study demonstrated overexpression of USP4 in several types of human cancer and that USP4 positively contributes to cell transformation by negatively regulating p53 levels (9). Both murine and human USP4 have been shown to interact with the Rb family of tumor suppressor proteins, providing additional mechanistic evidence of a role for USP4 in cellular transformation (10, 11).
- Nijman, S.M. et al. (2005) Cell 123, 773-86.
- Nalepa, G. et al. (2006) Nat Rev Drug Discov 5, 596-613.
- Gupta, K. et al. (1994) Oncogene 9, 1729-31.
- Gupta, K. et al. (1993) Oncogene 8, 2307-10.
- Papa, F.R. and Hochstrasser, M. (1993) Nature 366, 313-9.
- Gray, D.A. et al. (1995) Oncogene 10, 2179-83.
- Gilchrist, C.A. et al. (1997) J Biol Chem 272, 32280-5.
- Gilchrist, C.A. and Baker, R.T. (2000) Biochim Biophys Acta 1481, 297-309.
- Zhang, X. et al. (2011) EMBO J 30, 2177-89.
- Blanchette, P. et al. (2001) Oncogene 20, 5533-7.
- DeSalle, L.M. et al. (2001) Oncogene 20, 5538-42.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.